Ethan A. Skerry
212-430-2670
eskerry@fenwick.com
Partner
Corporate
Ethan A.
Skerry
Ethan A.
Skerry
Partner
Corporate
Ethan is a leading technology and life sciences M&A lawyer who has completed hundreds of transactions across a wide range of industries, including software, gaming, e-commerce, artificial intelligence, social networking and life sciences. Ethan represents both public and private companies on acquisitions, sales and other complex strategic and financing transactions. Ethan also acts as an outside advisor to industry disrupting technology and life sciences companies on corporate governance and other matters, and regularly represents venture capital and private equity investors in investments.
Ethan’s work has been consistently recognized by leading legal publications, such as Chambers USA, The Legal 500, Super Lawyers and The BTI Consulting Group.
Ethan currently serves as a member of Fenwick’s compensation committee, and previously served as a member of the firm’s executive committee. He is resident in Fenwick’s New York office.
Ethan "has a strong knowledge base and amazing negotiation skills. He finds viable solutions to efficiently navigate extremely complex transactions."
Chambers USA, Client Quote
2021 Edition
- Yuga Labs in its acquisition of WENEW
- OrderGroovein its recapitalization led by Primus Capital
- Muck Rack in its growth financing led by Susquehanna Growth Equity
- Molekule in its merger with Aeroclear
- Billie in its sale to Edgewell Personal Care
- Nextdoor in its de-SPAC merger with Khosla Ventures Acquisition Co. II
- Buzzfeed in its de-SPAC merger with 890 Fifth Avenue Partners SPAC and in its acquisition of Complex Networks
- Peloton in multiple acquisition transactions, including its acquisition of Precor
- CLEAR in its acquisition of Whyline
- UnitedSiC in its sale to Qorvo
- Statespace in its acquisition of ProGuides
- Stripe in its acquisitions of Paystack and TaxJar
- Mobilize in its sale to EveryAction
- CTI Towers in its sale to Melody
- ThousandEyes in its acquisition by Cisco
- Seal Software in its acquisition by DocuSign
- DocuSign in its acquisition of LiveOak
- eSilicon in the divestiture of certain assets to Synopsys and sale to Inphi
- SignalFX in its $1.05B sale to Splunk
- Segovia in its acquisition by Crown Agents Bank
- Mphasis in its acquisitions of BlinkUX and Stelligent Systems
- Some Spider Studios in its sale to Bustle Digital Group
- Lendup in the restructuring of its credit card business
- Jama Software in its recapitalization by Insight Venture Partners
- Mimosa Networks in its acquisition by Airspan Networks
- Grovo Learning in its acquisition by Cornerstone OnDemand
- Delphi in its acquisition of nuTonomy
- Gigya in its acquisition by SAP
- Bonobos in its acquisition by Walmart
- The principal investor in the acquisition of Blue Man Group by Cirque du Soleil
- Bitly in its acquisition by Spectrum Equity
- Yuga Labs in its acquisition of WENEW
- OrderGroovein its recapitalization led by Primus Capital
- Muck Rack in its growth financing led by Susquehanna Growth Equity
- Molekule in its merger with Aeroclear
- Billie in its sale to Edgewell Personal Care
- Nextdoor in its de-SPAC merger with Khosla Ventures Acquisition Co. II
- Buzzfeed in its de-SPAC merger with 890 Fifth Avenue Partners SPAC and in its acquisition of Complex Networks
- Peloton in multiple acquisition transactions, including its acquisition of Precor
- CLEAR in its acquisition of Whyline
- UnitedSiC in its sale to Qorvo
- Statespace in its acquisition of ProGuides
- Stripe in its acquisitions of Paystack and TaxJar
- Mobilize in its sale to EveryAction
- CTI Towers in its sale to Melody
- ThousandEyes in its acquisition by Cisco
- Seal Software in its acquisition by DocuSign
- DocuSign in its acquisition of LiveOak
- eSilicon in the divestiture of certain assets to Synopsys and sale to Inphi
- SignalFX in its $1.05B sale to Splunk
- Segovia in its acquisition by Crown Agents Bank
- Mphasis in its acquisitions of BlinkUX and Stelligent Systems
- Some Spider Studios in its sale to Bustle Digital Group
- Lendup in the restructuring of its credit card business
- Jama Software in its recapitalization by Insight Venture Partners
- Mimosa Networks in its acquisition by Airspan Networks
- Grovo Learning in its acquisition by Cornerstone OnDemand
- Delphi in its acquisition of nuTonomy
- Gigya in its acquisition by SAP
- Bonobos in its acquisition by Walmart
- The principal investor in the acquisition of Blue Man Group by Cirque du Soleil
- Bitly in its acquisition by Spectrum Equity
- Aceragen in its merger with Idera Pharmaceuticals
- Market Access Transformation in its sale to Genesis Research
- Klara Health in its sale to Modernizing Medicine
- CareSignal in its sale to Lightbeam Health Solutions
- PlushCare in its acquisition by Accolade
- Sema4 in its acquisition of GeneDx and its de-SPAC merger with CM Life Sciences
- ZipDrug in its acquisition by Anthem Health
- Chinook Therapeutics in its merger with Aduro Biotech
- Mavupharma in its acquisition by Abbvie
- Propeller Health in its acquisition by ResMed
- Corium International in its acquisition by Gurnet Point Capital
- Celenex in its acquisition by Amicus Therapeutics
- Channel Medsystems in its merger agreement with Boston Scientific
- Covis Pharma and Covis Injectables in their all-cash $1.2B sale of assets to Concordia Healthcare
- G&W Laboratories in its acquisition of Teva Pharmaceuticals’ manufacturing plant and portfolio of pharmaceutical products
- Cerberus Capital Management in its $105M control investment in PaxVax
- Caladrius in its acquisition of California Stem Cell
- Covis Pharma in its acquisitions of pharmaceutical products from Sanofi and Bayer AG
- Cerberus Capital Management in its investment in Covis Pharma
- Princeton Pharma Holdings and its wholly owned subsidiary Aton Pharma in their $318M acquisition by Valeant Pharmaceuticals
- Celldex Therapeutics in its $93.5M acquisition of CuraGen, and in its $129M stock-for-stock merger with Avant Immunotherapeutics
- Vital Signs in its $870M cash merger with GE Healthcare
- LifeCell in its $1.7B two-step tender offer/merger with Kinetic Concepts
- GF Capital Private Equity Fund in its acquisition of the assets of Airborne Health
- Tamir Biotechnology in its sale to Orgenesis
- Merck in the combination of its ILÚM Health Solutions business with UPMC's Infectious Disease Connect
- Aceragen in its merger with Idera Pharmaceuticals
- Market Access Transformation in its sale to Genesis Research
- Klara Health in its sale to Modernizing Medicine
- CareSignal in its sale to Lightbeam Health Solutions
- PlushCare in its acquisition by Accolade
- Sema4 in its acquisition of GeneDx and its de-SPAC merger with CM Life Sciences
- ZipDrug in its acquisition by Anthem Health
- Chinook Therapeutics in its merger with Aduro Biotech
- Mavupharma in its acquisition by Abbvie
- Propeller Health in its acquisition by ResMed
- Corium International in its acquisition by Gurnet Point Capital
- Celenex in its acquisition by Amicus Therapeutics
- Channel Medsystems in its merger agreement with Boston Scientific
- Covis Pharma and Covis Injectables in their all-cash $1.2B sale of assets to Concordia Healthcare
- G&W Laboratories in its acquisition of Teva Pharmaceuticals’ manufacturing plant and portfolio of pharmaceutical products
- Cerberus Capital Management in its $105M control investment in PaxVax
- Caladrius in its acquisition of California Stem Cell
- Covis Pharma in its acquisitions of pharmaceutical products from Sanofi and Bayer AG
- Cerberus Capital Management in its investment in Covis Pharma
- Princeton Pharma Holdings and its wholly owned subsidiary Aton Pharma in their $318M acquisition by Valeant Pharmaceuticals
- Celldex Therapeutics in its $93.5M acquisition of CuraGen, and in its $129M stock-for-stock merger with Avant Immunotherapeutics
- Vital Signs in its $870M cash merger with GE Healthcare
- LifeCell in its $1.7B two-step tender offer/merger with Kinetic Concepts
- GF Capital Private Equity Fund in its acquisition of the assets of Airborne Health
- Tamir Biotechnology in its sale to Orgenesis
- Merck in the combination of its ILÚM Health Solutions business with UPMC's Infectious Disease Connect
- The Estée Lauder Companies in its $1.4B acquisition of Too Faced Cosmetics and its acquisitions of Le Labo and Applied Genetics Incorporated Dermatics
- Indorama Ventures, in its acquisitions of CEPSA Chimie Montreal, the U.S. and Mexican polyester and PET resins business of Invista and FiberVisions from Snow Phipps Group
- Cytec Industries in the $105M acquisition of its pressure-sensitive adhesives business by Henkel
- The Estée Lauder Companies in its $1.4B acquisition of Too Faced Cosmetics and its acquisitions of Le Labo and Applied Genetics Incorporated Dermatics
- Indorama Ventures, in its acquisitions of CEPSA Chimie Montreal, the U.S. and Mexican polyester and PET resins business of Invista and FiberVisions from Snow Phipps Group
- Cytec Industries in the $105M acquisition of its pressure-sensitive adhesives business by Henkel
Recognition Recognition Recognition
Recognition Recognition Recognition
Recognition
Chambers USA
2021-2023
Ranked Ethan as a leading lawyer for New York Corporate/M&A law.
The Legal 500
2022
Has repeatedly honored Ethan for his M&A work and most recently recognized him for excellence in the area of M&A: Middle Market for transactions in the $500 million - $999 million range.
Recognition
Chambers USA
2021-2023
Ranked Ethan as a leading lawyer for New York Corporate/M&A law.
The Legal 500
2022
Has repeatedly honored Ethan for his M&A work and most recently recognized him for excellence in the area of M&A: Middle Market for transactions in the $500 million - $999 million range.